Contact us

877-469-1TRM
424-208-8866

Phase 2 Study of HM10460A or Pegfilgrastim Use for the Management of Neutropenia in Breast Cancer Patients

Phase 2, Open-Label, Dose-Ranging Study of HM10460A or Pegfilgrastim Use for the Management of Neutropenia in Patients With Breast Cancer Who Are Candidates for Adjuvant and Neoadjuvant Chemotherapy With the Docetaxel + Cyclophosphamide (TC) Regimen

For more information, please visit ClinicalTrials.gov

Patient Population Investigational Product(s) Phase Status
High Risk Stage II, III or IV Breast Cancer HM10460A II Closed to Accrual